The role of brachytherapy (interventional radiotherapy) for primary and/or recurrent vulvar cancer: a Gemelli Vul.Can multidisciplinary team systematic review.
Advanced vulvar cancer
Brachytherapy
Interventional radiotherapy
Outcomes
Recurrences
Toxicity
Journal
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
14
12
2020
accepted:
19
01
2021
pubmed:
3
3
2021
medline:
1
12
2021
entrez:
2
3
2021
Statut:
ppublish
Résumé
The aim of our systematic review was to assess the role of interventional radiotherapy (IRT, brachytherapy) in the management of primary and/or recurrent vulvar carcinoma. A systematic research using PubMed, Scopus and Cochrane library was performed. ClinicalTrials.gov was searched for ongoing or recently completed trials, and PROSPERO was searched for ongoing or recently completed systematic reviews. Only full-text English-language articles related to IRT for treatment of primary or recurrent VC were identified and reviewed. Conference paper, survey, letter, editorial, book chapter and review were excluded. Time restriction (1990-2018) as concerns the years of the publication was considered. Primary disease: the median 5-year LC was 43.5% (range 19-68%); the median 5-year DFS was 44.5% (range 44-81%); the median 5-year OS was 50.5% (range 27-85%). Recurrent disease: the median 5-year DFS was 64% (range 56-72%) and the median 5-year OS was 45% (range 33%-57%). Acute ≥ grade 2 toxicity was reported in three patients (1.6%). The severe late toxicity rates (grade 3-4) ranged from 0% to 14.3% (median 7.7%). IRT as part of primary treatment for primary and/or recurrent vulvar cancer is associated with promising clinical outcomes.
Identifiants
pubmed: 33650029
doi: 10.1007/s12094-021-02557-1
pii: 10.1007/s12094-021-02557-1
doi:
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1611-1619Références
NCCN Guidelines. (2020). https://www.nccn.org/professionals/physician_gls/pdf/vulvar_blocks.pdf .
National Cancer Institute. (2020). https://www.cancer.gov/types/vulvar/hp .
Judson PL, Habermann EB, Baxter NN, et al. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol. 2006;107:1018–22.
doi: 10.1097/01.AOG.0000210268.57527.a1
Carter JS, Downs LS. Vulvar and vaginal cancer. Obstet Gynecol Clin North Am. 2012;39:213–31.
doi: 10.1016/j.ogc.2012.04.002
Beller U, Quinn MA, Benedet JL, et al. Carcinoma of the vulva. Int J Gynecol Obstet. 2006;95:S7–27.
doi: 10.1016/S0020-7292(06)60028-3
Prempree T, Amornmarn R. Radiation treatment of recurrent carcinoma of the vulva. Cancer. 1984;54:1943–9.
doi: 10.1002/1097-0142(19841101)54:9<1943::AID-CNCR2820540926>3.0.CO;2-Z
Bell JG, Lea JS, Reid GC. Complete groin lymphadenectomy with preservation of the fascia lata in the treatment of vulvar carcinoma. Gynecol Oncol. 2000;77:314–8.
doi: 10.1006/gyno.2000.5790
De Hullu JA, Hollema H, Lolkema S, et al. Vulvar carcinoma: the price of less radical surgery. Cancer. 2002;95:2331–8.
doi: 10.1002/cncr.10969
Kirby TO, Rocconi RP, Numnum TM, et al. Outcomes of Stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy. Gynecol Oncol. 2005;98:309–12.
doi: 10.1016/j.ygyno.2005.05.011
Andersen BL, Hacker NF. Psychosexual adjustment after vulvar surgery. Obstet Gynecol. 1983;62:457–62.
pubmed: 6888823
pmcid: 2722221
Gould N, Kamelle S, Tillmanns T, et al. Predictors of complications after inguinal lymphadenectomy. Gynecol Oncol. 2001;82:329–32.
doi: 10.1006/gyno.2001.6266
Lin JY, DuBeshter B, Angel C, Dvoretsky PM. Morbidity and recurrence with modifications of radical vulvectomy and groin dissection. Gynecol Oncol. 1992;47:80–6.
doi: 10.1016/0090-8258(92)90081-S
Hoffman MS. Squamous-cell carcinoma of the vulva: locally advanced disease. Best Pract Res Clin Obstet Gynaecol. 2003;17:635–47.
doi: 10.1016/S1521-6934(03)00051-8
Gentileschi S, Servillo M, Garganese G, et al. The lymphatic superficial circumflex iliac vessels deep branch perforator flap: a new preventive approach to lower limb lymphedema after groin dissection-preliminary evidence. Microsurgery. 2017;37:564–73.
doi: 10.1002/micr.30142
Gentileschi S, Servillo M, Garganese G, et al. Surgical therapy of vulvar cancer: how to choose the correct reconstruction? J Gynecol Oncol. 2016;27:e60.
doi: 10.3802/jgo.2016.27.e60
Gentileschi S, Servillo M, Garganese G, et al. Versatility of pedicled anterolateral thigh flap in gynecologic reconstruction after vulvar cancer extirpative surgery. Microsurgery. 2017;37:516–24.
doi: 10.1002/micr.30077
Fanfani F, Garganese G, Fagotti A, et al. Advanced vulvar carcinoma: is it worth operating? A perioperative management protocol for radical and reconstructive surgery. Gynecol Oncol. 2006;103:467–72.
doi: 10.1016/j.ygyno.2006.03.022
Woolderink JM, de Bock GH, de Hullu JA, et al. Patterns and frequency of recurrences of squamous cell carcinoma of the vulva. Gynecol Oncol. 2006;103:293–9.
doi: 10.1016/j.ygyno.2006.03.010
Ghebre RG, Posthuma R, Vogel RI, et al. Effect of age and comorbidity on the treatment and survival of older patients with vulvar cancer. Gynecol Oncol. 2011;121:595–9.
doi: 10.1016/j.ygyno.2011.02.005
Saito T, Tabata T, Ikushima H, et al. Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer. Int J Clin Oncol. 2018;23:201–34.
doi: 10.1007/s10147-017-1193-z
Alkatout I, Schubert M, Garbrecht N, et al. Vulvar cancer: epidemiology, clinical presentation, and management options. Int J Womens Health. 2015;7:305–13.
doi: 10.2147/IJWH.S68979
Amsbaugh MJ, Bhatt N, Hunter T, et al. Computed tomography planned interstitial brachytherapy for recurrent gynecologic cancer. Brachytherapy. 2015;14:600–5.
doi: 10.1016/j.brachy.2015.05.007
Kellas-Ślęczka S, Białas B, Fijałkowski M, et al. Interstitial high-dose-rate brachytherapy in locally advanced and recurrent vulvar cancer. J Contemp Brachytherapy. 2016;8:32–40.
doi: 10.5114/jcb.2016.58081
Laliscia C, Gadducci A, Fabrini MG, et al. Definitive radiotherapy for recurrent vulvar carcinoma after primary surgery: a two-institutional Italian experience. Tumori. 2019;105:225–30.
doi: 10.1177/0300891618811279
Castelnau-Marchand P, Escande A, Mazeron R, et al. Brachytherapy as part of the conservative treatment for primary and recurrent vulvar carcinoma. Brachytherapy. 2017;16:518–25.
doi: 10.1016/j.brachy.2017.01.005
Mahantshetty U, Naga P, Engineer R, et al. Clinical outcome of high dose rate interstitial brachytherapy in vulvar cancer: a single institutional experience. Brachytherapy. 2017;16:153–60.
doi: 10.1016/j.brachy.2016.10.003
Pohar S, Hoffstetter S, Peiffert D, Luporsi E, Pernot M. Effectiveness of brachytherapy in treating carcinoma of the vulva? Int J Radiat Oncol Biol Phys. 1995;32:1455–60.
doi: 10.1016/0360-3016(95)00109-C
Rao YJ, Chundury A, Schwarz JK, et al. Intensity modulated radiation therapy for squamous cell carcinoma of the vulva: treatment technique and outcomes. Adv Radiat Oncol. 2017;2:148–58.
doi: 10.1016/j.adro.2017.02.006
Rao YG, Caressa H, Chundury A, et al. Which patients with inoperable vulvar cancer may benefit from brachytherapy in addition to external beam radiation? A Surveillance, Epidemiology, and End Results analysis. Brachytherapy. 2017;16:831–40.
doi: 10.1016/j.brachy.2017.03.012
Seeger AR, Windschall A, Lotter M, et al. The role of interstitial brachytherapy in the treatment of vaginal and vulvar malignancies. Strahlenther Onkol. 2006;182:142–8.
doi: 10.1007/s00066-006-1461-8
Tewari K, Cappuccini F, Syed N, et al. Interstitial brachytherapy in the treatment of advanced and recurrent vulvar cancer. Am J Obstet Gynecol. 1999;181:91–8.
doi: 10.1016/S0002-9378(99)70441-2
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–6.
doi: 10.1016/0360-3016(95)00060-C
Raffetto N, Tombolini V, Santarelli M, Valeriani M, Galla DA and Enrici RM. Radiotherapy alone and chemoirradiation in recurrent squamous cell carcinoma of the vulva. Anticancer Res 2003; 23: 3105–3108. 32. Perez CA, Grigsby PW, Galakatos A, et al. Radiation therapy in management of carcinoma of the vulva with emphasis on conservation therapy. Cancer 1993; 71: 3707–3371.
Salom EM, Penalver M. Recurrent vulvar cancer. Curr Treat Options Oncol. 2002;3:143–53.
doi: 10.1007/s11864-002-0060-x
Fonseca-Moutinho JA. Recurrent vulvar cancer. Clin Obstet Gynecol. 2005;48:879–83.
doi: 10.1097/01.grf.0000179671.98939.fe
Kovács G, Tagliaferri L, Valentini V. Is an Interventional Oncology Center an advantage in the service of cancer patients or in the education? The Gemelli Hospital and INTERACTS experience. J Contemporary Brachytherapy. 2017;9:497–8.
doi: 10.5114/jcb.2017.72603
Tagliaferri L, Garganese G, D’Aviero A, et al. Multidisciplinary personalized approach in the management of vulvar cancer—the Vul.Can Team experience. Int J Gynecol Cancer 2020 May 30;ijgc-2020–001465.
Morganti AG, Pasquarelli L, Deodato F, Digesù C, Di Falco C, Dinapoli N. Videoconferencing to enhance the integration between clinical medicine and teaching: a feasibility study. Tumori Journal. 2008;94:822–9.
doi: 10.1177/030089160809400608
Kovács G, Tagliaferri L, Lancellotta V, et al. Interventional oncology: should interventional radiotherapy (brachytherapy) be integrated into modern treatment procedures. Turk J Oncol. 2019;34:16–22.
Mantovani G, Fragomeni SM, Inzani F, et al. Molecular pathways in vulvar squamous cell carcinoma: implications for target therapeutic strategies. J Cancer Res Clin Oncol. 2020;146:1647–58.
doi: 10.1007/s00432-020-03226-6
Tagliaferri L, Budrukkar A, Lenkowicz J, et al. ENT COBRA ONTOLOGY: the covariates classification system proposed by the Head & Neck and Skin GEC-ESTRO Working Group for interdisciplinary standardized data collection in head and neck patient cohorts treated with interventional radiotherapy (brachytherapy). J Contemp Brachytherapy. 2018;10:260–6.
doi: 10.5114/jcb.2018.76982
Tagliaferri L, Gobitti C, Colloca GF, et al. A new standardized data collection system for interdisciplinary thyroid cancer management: thyroid COBRA. Eur J Intern Med. 2018;53:73–8.
doi: 10.1016/j.ejim.2018.02.012
Tagliaferri L, Pagliara MM, Masciocchi C, et al. Nomogram for predicting radiation maculopathy in patients treated with Ruthenium-106 plaque brachytherapy for uveal melanoma. J Contemp Brachytherapy. 2017;9:540–7.
doi: 10.5114/jcb.2017.71795
Meldolesi E, van Soest J, Alitto AR, et al. VATE: VAlidation of high TEchnology based on large database analysis by learning machine Published Online: 19 Nov 2014. https://doi.org/ https://doi.org/10.2217/crc.14.34—COLORECTAL CANCERVOL. 3, NO. 5 REVIEW Free Access.
Lancellotta V, Guinot JL, Fionda B, et al. SKIN-COBRA (Consortium for Brachytherapy data Analysis) ontology: the first step towards interdisciplinary standardized data collection for personalized oncology in skin cancer. J Contemp Brachytherapy. 2020;12:105–10.
doi: 10.5114/jcb.2020.94579